Cardiovascular Effects of Incretin-Based Therapies: Integrating Mechanisms With Cardiovascular Outcome Trials
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
As the worldwide prevalence of diabetes and obesity continues to rise, so does the risk of debilitating cardiovascular complications. Given the significant association between diabetes and cardiovascular risk, the actions of glucose-lowering therapies within the cardiovascular system must be clearly defined. Incretin hormones, including GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), are gut hormones secreted in response to nutrient intake that maintain glycemic control by regulating insulin and glucagon release. GLP-1 receptor agonists (GLP-1Ras) and dipeptidyl peptidase 4 inhibitors (DPP-4is) represent two drug classes used for the treatment of type 2 diabetes mellitus (T2DM) that improve glucose regulation through stimulating the actions of gut-derived incretin hormones or inhibiting their degradation, respectively. Despite both classes acting to potentiate the incretin response, the potential cardioprotective benefits afforded by GLP-1Ras have not been recapitulated in cardiovascular outcome trials (CVOTs) evaluating DPP-4is. This review provides insights through discussion of clinical and preclinical studies to illuminate the physiological mechanisms that may underlie and reconcile observations from GLP-1Ra and DPP-4i CVOTs. Furthermore, critical knowledge gaps and areas for further investigation will be emphasized to guide future studies and, ultimately, facilitate improved clinical management of cardiovascular disease in T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are hormones released in response to nutrient intake that potentiate glucose-stimulated insulin secretion (1).”
BackgroundSaxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 1×
“Interestingly, these results were not replicated in the Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) and CARMELINA, as their HF hospitalization rates did not differ among patients with T2DM, even between those with a history of HF or chronic kidney disease, and were independent of LV ejection frac…”
ResultAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“Endotheliumdependent vasodilation in response to acetylcholine was improved in preconstricted aortic rings isolated from WDfed Apoe / mice treated with liraglutide versus the control, which was abolished by cotreatment with the GLP1R antagonist exendin(9-39) (19).”
BackgroundMyocardial ischemia-reperfusion injury: a neglected therapeutic target
Hausenloy, D. J., & Yellon, D. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci62874 · Cited by 2,357 · cited 7×
“For example, the DPP-4–cleaved GLP-1 peptide GLP-1(9-36), which was originally thought to be inactive, may have direct vascular effects that improve cardiac function (22, 71).”
BackgroundInfluentialRosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., Alexander, J. H., Pencina, M., Toto, R. D., Wanner, C., et al. (2019) · JAMA · doi:10.1001/jama.2018.18269 · Cited by 1,084 · cited 1×
“The Cardiovascular and Renal Microvascular Outcome Study With Linagliptin (CARMELINA) demonstrated both cardiovascular and renal safety of linagliptin versus placebo (43).”
BackgroundBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“For example, the DPP-4–cleaved GLP-1 peptide GLP-1(9-36), which was originally thought to be inactive, may have direct vascular effects that improve cardiac function (22, 71).”
BackgroundScirica, B. M., Braunwald, E., Raz, I., Cavender, M. A., Morrow, D. A., Jarolim, P., Udell, J. A., Mosenzon, O., Im, K., Umez-Eronini, A. A., et al. (2014) · Circulation · doi:10.1161/circulationaha.114.010389 · Cited by 725
Research works printed but not linked: 44
- Gopal, 2020, The impact of antidiabetic therapies on diastolic dysfunction and diabetic cardiomyopathy, Front Physiol, 11, 603247, 10.3389/fphys.2020.603247 · DOI
- Sanada, 2021, Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better, Sci Rep, 11, 1425, 10.1038/s41598-020-80894-x · DOI · Paper page
- Sudo, 2017, Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: serial in vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits, Atherosclerosis, 265, 283, 10.1016/j.atherosclerosis.2017.06.920 · DOI
- Koska, 2021, The effect of exenatide once weekly on carotid atherosclerosis in individuals with type 2 diabetes: an 18-month randomized placebo-controlled study, Diabetes Care, 44, 1385, 10.2337/dc20-2014 · DOI · Paper page
- Fonseca, 2014, Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials, J Diabetes Complications, 28, 399, 10.1016/j.jdiacomp.2014.01.009 · DOI · Paper page
- Li, 2014, Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients, Cardiovasc Diabetol, 13, 36, 10.1186/1475-2840-13-36 · DOI · Paper page
- Gaspari, 2011, A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model, Diab Vasc Dis Res, 8, 117, 10.1177/1479164111404257 · DOI · Paper page
- Moberly, 2012, Intracoronary glucagon-like peptide 1 preferentially augments glucose uptake in ischemic myocardium independent of changes in coronary flow, Exp Biol Med (Maywood), 237, 334, 10.1258/ebm.2011.011288 · DOI
- Lønborg, 2012, Exenatide reduces final infarct size in patients with ST-segment-elevation myocardial infarction and short-duration of ischemia, Circ Cardiovasc Interv, 5, 288, 10.1161/CIRCINTERVENTIONS.112.968388 · DOI · Paper page
- Holman, 2017, Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes, N Engl J Med, 377, 1228, 10.1056/NEJMoa1612917 · DOI · Paper page
- Bao, 2011, Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency, PLoS One, 6, e23570, 10.1371/journal.pone.0023570 · DOI · Paper page
- Sassoon, 2017, Glucagon-like peptide 1 receptor activation augments cardiac output and improves cardiac efficiency in obese swine after myocardial infarction, Diabetes, 66, 2230, 10.2337/db16-1206 · DOI · Paper page
- Shiraki, 2019, GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy, Cardiovasc Diabetol, 18, 164, 10.1186/s12933-019-0966-2 · DOI
- Almutairi, 2021, The GLP-1 receptor agonist liraglutide increases myocardial glucose oxidation rates via indirect mechanisms and mitigates experimental diabetic cardiomyopathy, Can J Cardiol, 37, 140, 10.1016/j.cjca.2020.02.098 · DOI · Paper page
- Ding, 2019, Exenatide protects against cardiac dysfunction by attenuating oxidative stress in the diabetic mouse heart, Front Endocrinol (Lausanne), 10, 202, 10.3389/fendo.2019.00202 · DOI · Paper page
- Hussein, 2020, Comparative study of the effects of GLP1 analog and SGLT2 inhibitor against diabetic cardiomyopathy in type 2 diabetic rats: possible underlying mechanisms, Biomedicines, 8, 43, 10.3390/biomedicines8030043 · DOI
- Koyani, 2018, Saxagliptin but not sitagliptin inhibits CaMKII and PKC via DPP9 inhibition in cardiomyocytes, Front Physiol, 9, 1622, 10.3389/fphys.2018.01622 · DOI
- Mulvihill, 2014, Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors, Endocr Rev, 35, 992, 10.1210/er.2014-1035 · DOI · Paper page
- Yang, 2016, Increased plasma dipeptidyl peptidase-4 activities in patients with coronary artery disease, PLoS One, 11, e0163027, 10.1371/journal.pone.0163027 · DOI
- Zheng, 2015, Increased plasma dipeptidyl peptidase-4 activities are associated with high prevalence of subclinical atherosclerosis in Chinese patients with newly diagnosed type 2 diabetes: a cross-sectional study, Atherosclerosis, 242, 580, 10.1016/j.atherosclerosis.2015.07.042 · DOI
- Barchetta, 2019, Greater circulating DPP4 activity is associated with impaired flow-mediated dilatation in adults with type 2 diabetes mellitus, Nutr Metab Cardiovasc Dis, 29, 1087, 10.1016/j.numecd.2019.07.010 · DOI
- Cho, 2019, Soluble dipeptidyl peptidase-4 levels are associated with decreased renal function in patients with type 2 diabetes mellitus, Diabetes Metab J, 43, 97, 10.4093/dmj.2018.0030 · DOI
- Nargis, 2018, Significance of circulatory DPP4 activity in metabolic diseases, IUBMB Life, 70, 112, 10.1002/iub.1709 · DOI · Paper page
- Lettau, 2020, Degranulation of human cytotoxic lymphocytes is a major source of proteolytically active soluble CD26/DPP4, Cell Mol Life Sci, 77, 751, 10.1007/s00018-019-03207-0 · DOI
- Ghorpade, 2018, Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance, Nature, 555, 673, 10.1038/nature26138 · DOI · Paper page
- Varin, 2019, Circulating levels of soluble dipeptidyl peptidase-4 are dissociated from inflammation and induced by enzymatic DPP4 inhibition, Cell Metab, 29, 320, 10.1016/j.cmet.2018.10.001 · DOI · Paper page
- Lee, 2019, Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation, Sci Adv, 5, eaaw4176, 10.1126/sciadv.aaw4176 · DOI
- Ohnuma, 2005, CD26 mediates dissociation of Tollip and IRAK-1 from caveolin-1 and induces upregulation of CD86 on antigen-presenting cells, Mol Cell Biol, 25, 7743, 10.1128/MCB.25.17.7743-7757.2005 · DOI
- Baggio, 2020, Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans, Nat Commun, 11, 3766, 10.1038/s41467-020-17556-z · DOI
- Ikeda, 2013, Soluble CD26/dipeptidyl peptidase IV enhances the transcription of IL-6 and TNF-α in THP-1 cells and monocytes, PLoS One, 8, e66520, 10.1371/journal.pone.0066520 · doi:10.1371/journal.pone.0066520
- Lee, 2016, Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate, Metabolism, 65, 89, 10.1016/j.metabol.2015.10.002 · DOI
- Kubota, 2016, DPP-4 inhibition has beneficial effects on the heart after myocardial infarction, J Mol Cell Cardiol, 91, 72, 10.1016/j.yjmcc.2015.12.026 · DOI
- Sauvé, 2010, Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice, Diabetes, 59, 1063, 10.2337/db09-0955 · DOI · Paper page
- Batchu, 2018, The dipeptidyl peptidase 4 substrate CXCL12 has opposing cardiac effects in young mice and aged diabetic mice mediated by Ca2+ flux and phosphoinositide 3-kinase γ, Diabetes, 67, 2443, 10.2337/db18-0410 · DOI
- Mulvihill, 2016, Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice, Diabetes, 65, 742, 10.2337/db15-1224 · DOI · Paper page
- Gross, 2016, Combined therapy with sitagliptin plus granulocyte-colony stimulating factor in patients with acute myocardial infarction-Long-term results of the SITAGRAMI trial, Int J Cardiol, 215, 441, 10.1016/j.ijcard.2016.04.134 · DOI
- Crowley, 2017, Metformin use may moderate the effect of DPP-4 inhibitors on cardiovascular outcomes, Diabetes Care, 40, 1787, 10.2337/dc17-1528 · DOI · Paper page
- Wang, 2017, Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients, Medicine (Baltimore), 96, e7638, 10.1097/MD.0000000000007638 · DOI
- Mulherin, 2011, Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell, Endocrinology, 152, 4610, 10.1210/en.2011-1485 · DOI · Paper page
- Dugani, 2021, Association of lipid, inflammatory, and metabolic biomarkers with age at onset for incident coronary heart disease in women, JAMA Cardiol, 6, 437, 10.1001/jamacardio.2020.7073 · DOI · Paper page
- Goodwill, 2014, Glucagon-like peptide-1 (7-36) but not (9-36) augments cardiac output during myocardial ischemia via a Frank-Starling mechanism, Basic Res Cardiol, 109, 426, 10.1007/s00395-014-0426-9 · DOI
- Varin, 2020, Hematopoietic cell- versus enterocyte-derived dipeptidyl peptidase-4 differentially regulates triglyceride excursion in mice, JCI Insight, 5, e140418, 10.1172/jci.insight.140418 · DOI
- Grasset, 2017, A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism, Cell Metab, 26, 278, 10.1016/j.cmet.2017.06.003 · DOI
- Overgaard, 2021, Levels of circulating semaglutide determine reductions in HbA1c and body weight in people with type 2 diabetes, Cell Rep Med, 2, 100387, 10.1016/j.xcrm.2021.100387 · DOI · Paper page
Cited by
Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2022) · Metabolites · doi:10.3390/metabo12020183 · Cited by 86
“, GLP-1RA-mediated cardiovascular protection could be mainly attributed to their vascular anti-inflammatory and anti-atherosclerotic actions, alongside improvements in heart glucose metabolism, fibrosis, oxidative stress, cardiomyocytes viability, and, even though to a small extent, in blood pressure [9].”
Background2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure
Kittleson, M. M., Benjamin, E. J., Blumer, V., Harrington, J., Januzzi, J. L., McMurray, J. J. V., & Vest, A. R. (2025) · JACC · doi:10.1016/j.jacc.2025.05.008 · Cited by 79
Lingvay, I., Mosenzon, O., Brown, K., Cui, X., O’Neill, C., Fernández Landó, L., & Patel, H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01797-5 · Cited by 55
“Natriuresis [32], direct vasodilation [33], reductions in sympathetic nervous system activity [34], extracellular volume and midregional-pro-atrial natriuretic peptide (proANP) [33, 35] are potential direct mechanisms for GLP-1 RAs leading to SBP lowering.”
BackgroundRen, Y., Chen, Y., Zheng, W., Kong, W., Liao, Y., Zhang, J., Wang, M., & Zeng, T. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16366 · Cited by 59
Pérez-Belmonte, L. M., Sanz-Cánovas, J., García de Lucas, M. D., Ricci, M., Avilés-Bueno, B., Cobos-Palacios, L., Pérez-Velasco, M. A., López-Sampalo, A., Bernal-López, M. R., Jansen-Chaparro, S., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.851035 · Cited by 35
Metadata
- Authors
- Ussher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2022-01-11
- Volume
- 71
- Issue
- 2
- Pages
- 173-183
- ISSN
- 0012-1797 (ISSN-L)
- OpenAlex
- W4205521731
- Cited by
- 50
- References
- 32
- FWCI
- 6.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.